TY - JOUR
T1 - Positron emission tomography (PET) for prediction of glioma histology
T2 - Protocol for an individual-level data meta-analysis of test performance
AU - Trikalinos, Nikolaos A.
AU - Nihashi, Takashi
AU - Evangelou, Evangelos
AU - Terasawa, Teruhiko
N1 - Publisher Copyright:
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Introduction Gliomas, the most commonly diagnosed primary brain tumours, are associated with varied survivals based, in part, on their histological subtype. Therefore, accurate pretreatment tumour grading is essential for patient care and clinical trial design. Methods and analysis We will perform an individual-level data meta-analysis of published studies to evaluate the ability of different types of positron emission tomography (PET) to differentiate high from low-grade gliomas. We will search PubMed and Scopus from inception through 30 July 2017 with no language restriction and full-text evaluation of potentially relevant articles. We will choose studies that assess PET using 18-Fludeoxyglucose (18F-FDG), l-[Methyl-()11C]Methionine (11C-MET), 18F-Fluoro-Ethyl-Tyrosine (18F-FET) or (18)F-Fluorothymidine (18F-FLT)for grading, verified with histological confirmation. We will include both prospective and retrospective studies. Bias will be assessed by two reviewers with the Quality Assessment of Diagnostic Accuracy Studies-2 tool and as per method described by Deeks et al. Ethics and dissemination Ethics approval was not applicable, as this is a meta-analytic study. Results of the analysis will be submitted for publication in a peer-reviewed journal. PROSPERO registration number CRD42017078649.
AB - Introduction Gliomas, the most commonly diagnosed primary brain tumours, are associated with varied survivals based, in part, on their histological subtype. Therefore, accurate pretreatment tumour grading is essential for patient care and clinical trial design. Methods and analysis We will perform an individual-level data meta-analysis of published studies to evaluate the ability of different types of positron emission tomography (PET) to differentiate high from low-grade gliomas. We will search PubMed and Scopus from inception through 30 July 2017 with no language restriction and full-text evaluation of potentially relevant articles. We will choose studies that assess PET using 18-Fludeoxyglucose (18F-FDG), l-[Methyl-()11C]Methionine (11C-MET), 18F-Fluoro-Ethyl-Tyrosine (18F-FET) or (18)F-Fluorothymidine (18F-FLT)for grading, verified with histological confirmation. We will include both prospective and retrospective studies. Bias will be assessed by two reviewers with the Quality Assessment of Diagnostic Accuracy Studies-2 tool and as per method described by Deeks et al. Ethics and dissemination Ethics approval was not applicable, as this is a meta-analytic study. Results of the analysis will be submitted for publication in a peer-reviewed journal. PROSPERO registration number CRD42017078649.
KW - glioma
KW - meta-analysis
KW - pet
UR - http://www.scopus.com/inward/record.url?scp=85052835840&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2017-020187
DO - 10.1136/bmjopen-2017-020187
M3 - Article
C2 - 29455169
AN - SCOPUS:85052835840
SN - 2044-6055
VL - 8
JO - BMJ Open
JF - BMJ Open
IS - 2
M1 - e020187
ER -